Segall Bryant & Hamill LLC Lowers Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Segall Bryant & Hamill LLC lessened its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 42.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,515 shares of the specialty pharmaceutical company's stock after selling 16,468 shares during the period. Segall Bryant & Hamill LLC owned about 0.07% of Collegium Pharmaceutical worth $672,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Invesco Ltd. increased its stake in Collegium Pharmaceutical by 19.5% during the 4th quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company's stock worth $50,876,000 after buying an additional 289,335 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Collegium Pharmaceutical by 0.3% in the fourth quarter. Renaissance Technologies LLC now owns 1,661,549 shares of the specialty pharmaceutical company's stock valued at $47,603,000 after acquiring an additional 5,480 shares during the last quarter. Emerald Advisers LLC lifted its holdings in Collegium Pharmaceutical by 1.8% in the first quarter. Emerald Advisers LLC now owns 826,475 shares of the specialty pharmaceutical company's stock valued at $24,670,000 after acquiring an additional 14,795 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in Collegium Pharmaceutical by 18.1% in the first quarter. Massachusetts Financial Services Co. MA now owns 713,854 shares of the specialty pharmaceutical company's stock valued at $21,309,000 after acquiring an additional 109,655 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust lifted its holdings in Collegium Pharmaceutical by 0.8% in the first quarter. Emerald Mutual Fund Advisers Trust now owns 574,080 shares of the specialty pharmaceutical company's stock valued at $17,136,000 after acquiring an additional 4,513 shares during the last quarter.

Insider Activity

In related news, Director John Gordon Freund sold 6,601 shares of the firm's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $30.62, for a total transaction of $202,122.62. Following the transaction, the director owned 70,658 shares of the company's stock, valued at $2,163,547.96. This trade represents a 8.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 2.51% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms recently commented on COLL. HC Wainwright reiterated a "buy" rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Monday, March 24th. Wall Street Zen cut Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, July 5th. Piper Sandler restated a "neutral" rating and set a $37.00 price target (up from $36.00) on shares of Collegium Pharmaceutical in a research note on Friday, May 9th. Finally, Needham & Company LLC restated a "buy" rating and set a $46.00 price target on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $43.75.

Collegium Pharmaceutical Stock Up 2.4%

Collegium Pharmaceutical stock traded up $0.76 during midday trading on Tuesday, reaching $31.67. The company's stock had a trading volume of 91,650 shares, compared to its average volume of 395,540. Collegium Pharmaceutical, Inc. has a fifty-two week low of $23.23 and a fifty-two week high of $42.29. The company has a quick ratio of 1.01, a current ratio of 1.08 and a debt-to-equity ratio of 3.30. The company has a market cap of $1.02 billion, a P/E ratio of 25.97 and a beta of 0.64. The business has a 50-day simple moving average of $30.17 and a 200-day simple moving average of $29.72.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share for the quarter, missing analysts' consensus estimates of $1.50 by ($0.01). The business had revenue of $177.76 million during the quarter, compared to analyst estimates of $174.96 million. Collegium Pharmaceutical had a net margin of 6.61% and a return on equity of 99.08%. The firm's quarterly revenue was up 22.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.45 earnings per share. On average, research analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Collegium Pharmaceutical announced that its Board of Directors has authorized a share buyback plan on Monday, July 7th that allows the company to repurchase $150.00 million in outstanding shares. This repurchase authorization allows the specialty pharmaceutical company to reacquire up to 15.4% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's management believes its shares are undervalued.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.